WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL

Ítems similars

• WCN24-847 SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
  per: Jonathan Barratt, et al.
  Publicat: (2024-04-01)
• WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
  per: Chee Kay Cheung, et al.
  Publicat: (2024-04-01)
• WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
  per: Bruce Hendry, et al.
  Publicat: (2025-02-01)
• WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
  per: Chee Kay Cheung, et al.
  Publicat: (2025-02-01)
• WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
  per: Radko Komers, et al.
  Publicat: (2024-04-01)